Oaktree Acquisition Corp III Life Sciences
OACC
20 hedge funds and large institutions have $89.8M invested in Oaktree Acquisition Corp III Life Sciences in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
45.45% more ownership
Funds ownership: 0% → 45.45% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$19.8M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$14.3M |
| 3 |
BGIM
Boussard & Gavaudan Investment Management
London,
United Kingdom
|
+$7.48M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$5.49M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$4.49M |
Top Sellers
OACC Hedge Fund Activity: Q4 2024 in Review
20 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Oaktree Acquisition Corp III Life Sciences (OACC) for Q4 2024, worth a combined $89.8M.
Buyers outnumbered sellers: 20 funds opened new OACC positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AQR Arbitrage, opening a new position worth an estimated $19.8M.
- 20 institutional investors held Oaktree Acquisition Corp III Life Sciences (OACC) as of Q4 2024, up from 0 in Q3 2024.
- Funds reported $89.8M of Oaktree Acquisition Corp III Life Sciences stock for Q4 2024.
- 20 funds opened new Oaktree Acquisition Corp III Life Sciences positions in Q4 2024 and 0 closed out, a net change of +20 holders.
- The largest Oaktree Acquisition Corp III Life Sciences buyer in Q4 2024 was AQR Arbitrage, an estimated $19.8M added.
Based on aggregated 13F filings for Q4 2024.